Program
Simvastatin
Also written as “simvastatin”, “ezetimibe (+) simvastatin” and “Fenofibrate/Simvastatin”.
Its studies are mostly in Hypercholesterolemia · Diabetes Mellitus, Type 2 · Hyperlipidemias · Cardiovascular Diseases · Hypertension, led by 11 companies.
Drug pageSimvastatin: every studyMany companies study it; this page follows only the 65 they lead. All 370 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organonits history only | 290 open or running | phase 4since Sep 7, 2005 | Sep 21, 2004 | none ahead |
| Abbottits history only | 80 open or running | phase 3since Mar 25, 2004 | Mar 25, 2004 | none ahead |
| Eli Lillyits history only | 60 open or running | phase 2since Apr 15, 2010 | Apr 15, 2010 | none ahead |
| GlaxoSmithKlineits history only | 60 open or running | phase 3since Oct 28, 2005 | Oct 28, 2005 | none ahead |
| Merckits history only | 60 open or running | phase 3since May 24, 2007 | May 24, 2007 | none ahead |
| Pfizerits history only | 40 open or running | phase 4since Sep 8, 2005 | Sep 8, 2005 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Jul 21, 2010 | Jul 21, 2010 | none ahead |
| Biogenits history only | 10 open or running | phase 4since Jun 25, 2007 | Jun 25, 2007 | none ahead |
| Entero Therapeuticsits history only | 10 open or running | early phase 1since Oct 3, 2016 | Oct 3, 2016 | none ahead |
| Medtronic | 10 open or running | early phase 1since Jul 21, 2008 | Jul 21, 2008 | none ahead |
| Viatrisits history only | 10 open or running | phase 4since Aug 30, 2005 | Aug 30, 2005 | none ahead |
Also a collaborator on its studies: Immunogenics, Regeneron Pharmaceuticals, Celerion and Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Medtronic only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 21, 2008First study: early phase 1 study in Peripheral Arterial DiseaseFirst studyNCT00720577 · 164 enrolled
TargetBeta
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule
Other programs on HMGCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Atorvastatinrule | Viatris | phase 4 | 186 |
| rosuvastatinrule | AstraZeneca | phase 4 | 184 |
| pitavastatinrule | Kowa | phase 4 | 36 |
Studies
The one study Medtronic leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00720577Peripheral Arterial Disease | Early 1 | Completed | Jul 2007 | 164 |
How it is read
Names in the registry
- “Simvastatin”, 44 entries
- “simvastatin”, 14 entries
- “ezetimibe (+) simvastatin”, 9 entries
- “Fenofibrate/Simvastatin”, 5 entries
- “Ezetimibe + Simvastatin”, 4 entries
Codes read as this program: MK0733.
Conditions, from the studies’ own filings
- Hypercholesterolemia, 35 studies
- Diabetes Mellitus, Type 2, 9 studies
- Hyperlipidemias, 7 studies
- Cardiovascular Diseases, 3 studies
- Hypertension, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.